Pharmacoeconomic Review Report: Glecaprevir / Pibrentasvir (Maviret): (AbbVie Corporation) [Internet]

Excerpt

Glecaprevir/pibrentasvir (GP) is a fixed-dose combination of two pan-genotypic direct-acting antiviral (DAA) drugs: glecaprevir, a nonstructural viral protein 3/4A (NS3/4A) protease inhibitor; and pibrentasvir, a nonstructural viral protein 5A (NS5A) inhibitor. GP is indicated for the treatment of adult patients with chronic hepatitis C virus (HCV) genotype 1, 2, 3, 4, 5, or 6 infection with or without compensated cirrhosis (Table 2). The recommended dose is three tablets (glecaprevir 300 mg / pibrentasvir 120 mg) once daily for 8 to 16 weeks, depending on the patient’s prior treatment experience, genotype and whether cirrhosis is present. At the time of submission, the manufacturer submitted a price of $797.62 for three tablets. This price was reduced by the manufacturer during the review to $714.29 for three tablets, reflecting an approximate 10% reduction in the original price, and corresponding to $40,000 for an 8-week (56-day) treatment, $60,000 for a 12-week (84-day) treatment and $80,000 for a 16-week (112-day) treatment.